Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETREMAC
2024-519364-40-00Phase 2Authorised
- Sponsor
- Helse Bergen
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palbociclib, olaparib and pertuzumab in breast cancer (8 arms), sponsored by Helse Bergen. Planned start Nov 2024; status: authorised.
02
Drugs
palbociclibolaparibpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-519364-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519364-40-00.